title: Local recurrence after initial multidisciplinary management of soft tissue sarcoma: is there a way out?
abstract: BACKGROUND
  Multimodality treatment of primary soft tissue sarcoma by expert teams reportedly affords a low incidence of local recurrence. Despite advances, treatment of local recurrence remains difficult and is not standardized.
  
  
  OBJECTIVE
  We (1) determined the incidence of local recurrence from soft tissue sarcoma; (2) compared characteristics of the recurrent tumors with those of the primary ones; (3) evaluated local recurrences, metastases and death according to treatments; and (4) explored the relationship between the diagnosis of local recurrence and the occurrence of metastases.
  
  
  METHODS
  From our prospective database, we identified 618 soft tissue sarcomas. Thirty-seven of the 618 patients (6%) had local recurrence. Leiomyosarcoma was the most frequent diagnosis (eight of 37). The mean delay from original surgery was 22 months (range, 2-75 months). Mean size was 4.8 cm (range, 0.4-28.0 cm). Median followup after local recurrence was 16 months (range, 0-98 months).
  
  
  RESULTS
  Recurrent tumors had a tendency toward becoming deeper seated and higher graded. Nineteen of the 37 patients with recurrence underwent limb salvage (nine free flaps) and six had an amputation. Twenty-two (59%) had metastases, including 10 occurring after the local recurrence event at an average delay of 21 months (range, 1-34 months). Six patients developed additional local recurrences, with no apparent difference in risk between amputation (two of six) and limb salvage (four of 19).
  
  
  CONCLUSIONS
  Patients with a local recurrence of a soft tissue sarcoma have a poor prognosis. Limb salvage and additional radiotherapy remain possible but with substantial complications. Amputation did not prevent additional local recurrence or death.
authors.affiliation: McGill University Health Centre, 1650 Cedar Avenue, Montreal, QC, H3G 1A4, Canada.
authors.forename: Sarantis
authors.initials: S
authors.lastname: Abatzoglou
authors.forename: Robert E
authors.initials: RE
authors.lastname: Turcotte
authors.forename: Abdurahman
authors.initials: A
authors.lastname: Adoubali
authors.forename: Marc H
authors.initials: MH
authors.lastname: Isler
authors.forename: David
authors.initials: D
authors.lastname: Roberge
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000671:Amputation, Surgical; D016009:Chi-Square Distribution; D019992:Databases as Topic; D005260:Female; D006801:Humans; D015994:Incidence; D053208:Kaplan-Meier Estimate; D023821:Limb Salvage; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D009367:Neoplasm Staging; D019637:Orthopedic Procedures; D010348:Patient Care Team; D011792:Quebec; D018714:Radiotherapy, Adjuvant; D012086:Reoperation; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D012509:Sarcoma / Q000401:mortality / Q000556:secondary / Q000601:surgery*; D012983:Soft Tissue Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult